Strados Labs Company Profile

Background

Overview

Strados Labs is a Philadelphia-based medical technology company specializing in the development of smart sensor platforms aimed at enhancing the monitoring and management of chronic respiratory diseases. The company's flagship product, the RESP® Biosensor, is a wearable device that continuously records lung sounds, including coughs and wheezes, providing clinicians and researchers with real-time, objective data to improve patient outcomes.

Mission and Vision

Strados Labs is dedicated to transforming respiratory disease management by offering seamless, objective measurement of symptoms such as cough, wheeze, and breathing patterns through innovative technology. The company's mission is to provide tools that help life sciences companies improve understanding of treatment response in clinical trials and enable care teams to make earlier, more informed decisions that can prevent avoidable hospitalizations and improve outcomes.

Primary Area of Focus

The company's primary focus is on chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and infectious respiratory diseases like COVID-19 and RSV. By leveraging smart sensor technology and machine learning algorithms, Strados Labs aims to provide early detection and predictions of worsening respiratory conditions, thereby improving patient quality of life and reducing healthcare costs.

Industry Significance

Chronic respiratory diseases are among the most prevalent and difficult-to-manage health conditions, contributing to millions of emergency visits and hospital readmissions each year. Despite their impact, respiratory symptoms are often under-measured outside the clinic, leaving clinicians without the insight needed to detect potential exacerbations or fully understand how patients respond to treatments in daily life. Strados Labs addresses this gap by providing continuous, objective monitoring of respiratory health, thereby enhancing disease management and patient outcomes.

Key Strategic Focus

Core Objectives

• Early Detection and Prediction: Utilize smart sensor technology and machine learning to detect and predict worsening respiratory conditions, enabling timely interventions.

• Clinical Trial Support: Provide objective data to support pharmaceutical companies and clinical researchers in assessing treatment efficacy and patient responses.

• Remote Patient Monitoring: Enable healthcare providers to monitor patients outside of clinical settings, reducing hospital readmissions and improving chronic disease management.

Specific Areas of Specialization

• Wearable Respiratory Monitoring: Develop and deploy wearable devices that continuously capture lung sounds and other respiratory metrics.

• Data Analytics and Machine Learning: Apply advanced algorithms to analyze respiratory data, identifying patterns and predicting exacerbations.

• Regulatory Compliance: Ensure products meet stringent regulatory standards, including FDA clearances and CE markings.

Key Technologies Utilized

• Smart Sensors: Devices capable of capturing high-fidelity lung acoustics and other physiological signals.

• Machine Learning Algorithms: Tools for processing and analyzing complex respiratory data to provide actionable insights.

• Cloud-Based Platforms: Systems for data storage, processing, and remote access by healthcare providers and researchers.

Primary Markets Targeted

• Healthcare Providers: Hospitals, clinics, and home care services seeking advanced tools for respiratory disease management.

• Pharmaceutical Companies: Organizations conducting clinical trials requiring objective respiratory endpoints.

• Academic Researchers: Institutions studying respiratory diseases and treatment responses.

Financials and Funding

Funding History

As of February 2026, Strados Labs has secured approximately $11.65 million in funding through various rounds, including a pre-Series A funding round of $4.5 million in January 2022.

Recent Funding Rounds

• Pre-Series A Round (January 2022): Raised $4.5 million from investors such as SOSV, cultivate(MD), Wavemaker360 Health, Blu Venture Investors, and Broad Street Angels.

Notable Investors

• SOSV: A global venture capital firm investing in early-stage companies.

• cultivate(MD): A healthcare-focused venture fund.

• Wavemaker360 Health: An accelerator and venture fund supporting healthtech startups.

• Blu Venture Investors: A venture capital firm investing in early-stage technology companies.

• Broad Street Angels: An angel investment group based in Philadelphia.

Intended Utilization of Capital

The funds raised are intended to support the following initiatives:

• Product Development: Enhance the RESP® Biosensor and develop additional smart sensor platforms.

• Regulatory Approvals: Achieve necessary clearances and certifications for new products.

• Clinical Trials: Conduct studies to validate product efficacy and support clinical research.

• Market Expansion: Increase sales and marketing efforts to reach a broader customer base.

Pipeline Development

Key Pipeline Candidates

• RESP® Biosensor: A wearable device that continuously captures lung sounds, including coughs and wheezes, providing real-time data for clinicians and researchers.

Stages of Clinical Trials or Product Development

• FDA Clearances: Achieved FDA Class II 510(k) clearance for home use of the RESP® Biosensor in December 2021.

• CE Mark: Granted CE Mark for the RESP® Biosensor in late 2021.

Target Conditions

• Asthma: Monitoring and management of asthma symptoms to prevent exacerbations.

• COPD: Continuous assessment of COPD patients to reduce hospital readmissions.

• Infectious Respiratory Diseases: Detection of early signs of diseases like COVID-19 and RSV.

Relevant Timelines for Anticipated Milestones

• Product Enhancements: Ongoing development to improve device functionality and user experience.

• Regulatory Approvals: Pursuit of additional clearances and certifications for expanded indications.

• Market Expansion: Plans to increase adoption in both domestic and international markets.

Technological Platform and Innovation

Proprietary Technologies

• RESP® Biosensor: A wearable device that continuously records lung sounds, providing real-time data for clinicians and researchers.

Significant Scientific Methods

• Machine Learning Algorithms: Analyze complex respiratory data to identify patterns and predict exacerbations.

• Cloud-Based Data Processing: Enables remote access to patient data by healthcare providers and researchers.

Leadership Team

Nick Delmonico – CEO & Co-founder

Nick Delmonico is the co-founder and CEO of Strados Labs. Prior to Strados Labs, Nick worked in financial consulting at a Fortune 100 financial institution and in public accounting at a Big Four firm. During this time, Nick worked with multinational pharmaceutical companies, biotechnology firms, and large hospitals and health systems in the greater Philadelphia area. He received his master’s degree in Healthcare Management from Temple University’s Fox School of Business.

Richard Powers – Chief Product Officer & Co-founder

Richard Powers is the Chief Product Officer and co-founder of Strados Labs, where he leads product innovation and technical strategy. With over 25 years of experience in FDA-regulated medical device development, Richard has worked across Class III implantables, wearable sensors, and AI-driven respiratory diagnostics. He began his MedTech career at CardioMEMS as a graduate intern and advanced to CIO before co-founding Strados. Richard holds an M.S. in Electrical and Computer Engineering and an MBA from Georgia Tech.

Jason Kroh – Chief Technology Officer

Jason Kroh serves as Chief Technology Officer of Strados Labs, where he leads technology design, development, and manufacturing. He brings more than 25 years of experience in senior R&D and executive roles at innovative medical device start-ups. His expertise spans Class III implantable devices, combination products, and advanced novel wearable technologies. Recognized for his technical depth, Jason serves as an ongoing NSF grant reviewer, influencing the direction of emerging technologies.

Matt McCarty – Chief Commercial Officer

Matt McCarty serves as Chief Commercial Officer of Strados Labs, where he leads sales, marketing, partnerships, and commercial strategy. He brings nearly 20 years of experience across life sciences and clinical trials, including leadership roles at global contract research organizations and senior executive experience within the clinical trial endpoint market. Matt has worked extensively